Compare CULP & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | FEMY |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 37.2M |
| IPO Year | 1994 | 2021 |
| Metric | CULP | FEMY |
|---|---|---|
| Price | $3.21 | $0.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.83 |
| AVG Volume (30 Days) | 21.2K | ★ 462.5K |
| Earning Date | 03-09-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $213,237,000.00 | $1,629,108.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | $6.83 | $147.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 51.97 |
| 52 Week Low | $3.17 | $0.31 |
| 52 Week High | $5.64 | $1.76 |
| Indicator | CULP | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 49.50 |
| Support Level | N/A | $0.53 |
| Resistance Level | $4.05 | $0.57 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 9.62 | 72.56 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.